S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
NASDAQ:HALO

Halozyme Therapeutics News Headlines

$31.97
-0.38 (-1.17%)
(As of 01/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$31.88
$33.30
50-Day Range
$31.82
$41.06
52-Week Range
$31.79
$56.40
Volume
962,260 shs
Average Volume
1.02 million shs
Market Capitalization
$4.50 billion
P/E Ratio
11.46
Dividend Yield
N/A
Beta
1.3
Get Halozyme Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Halozyme Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

HALO
News Sentiment

0.01

0.27

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

HALO Articles
This Week

8

2

HALO Articles
Average Week



Halozyme Therapeutics (NASDAQ:HALO) News Headlines Today

SourceHeadline
marketbeat.com logoHalozyme Therapeutics (NASDAQ:HALO) Price Target Cut to $43.00
marketbeat.com - January 26 at 7:38 AM
MarketBeat logoHalozyme Therapeutics (NASDAQ:HALO) PT Lowered to $43.00 at Piper Sandler
americanbankingnews.com - January 26 at 8:26 AM
seekingalpha.com logoHalozyme issues lower than expected guidance for 2022
seekingalpha.com - January 10 at 11:19 AM
nasdaq.com logoHalozyme Therapeutics Issues 2022 Guidance; Projects Revenue Growth Of 23-26%
nasdaq.com - January 10 at 11:19 AM
finance.yahoo.com logoHALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOK
finance.yahoo.com - January 10 at 11:19 AM
MarketBeat logoHalozyme Therapeutics (NASDAQ:HALO) Releases FY22 Earnings Guidance
americanbankingnews.com - January 10 at 8:36 AM
MarketBeat logoFinancial Survey: Cardiff Oncology (NASDAQ:CRDF) vs. Halozyme Therapeutics (NASDAQ:HALO)
americanbankingnews.com - January 7 at 6:30 PM
finance.yahoo.com logoHalozyme to Present Virtually at the 40th Annual J.P. Morgan Health Care Conference
finance.yahoo.com - January 4 at 1:22 PM
finance.yahoo.com logoHALOZYME APPOINTS NEW GENERAL COUNSEL
finance.yahoo.com - December 13 at 9:01 PM
markets.businessinsider.com logoThe Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
markets.businessinsider.com - December 10 at 12:41 PM
finance.yahoo.com logoHALOZYME ANNOUNCES $750 MILLION THREE-YEAR SHARE REPURCHASE PROGRAM
finance.yahoo.com - December 9 at 5:55 PM
seekingalpha.com logoHalozyme Therapeutics (HALO) Investor Presentation - Slideshow
seekingalpha.com - December 7 at 5:58 PM
finance.yahoo.com logoHalozyme Therapeutics (HALO) Down 19.7% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - December 2 at 2:43 PM
finance.yahoo.com logoHalozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
finance.yahoo.com - December 1 at 6:10 PM
finance.yahoo.com logoHere's Why I Think Halozyme Therapeutics (NASDAQ:HALO) Is An Interesting Stock
finance.yahoo.com - November 5 at 10:19 AM
finance.yahoo.com logoHalozyme's Q3 Sales Boosted By Darzalex; Lifts FY21 Earnings Outlook
finance.yahoo.com - November 3 at 3:40 PM
fool.com logoHalozyme Therapeutics, inc (HALO) Q3 2021 Earnings Call Transcript
fool.com - November 3 at 12:11 AM
msn.com logoHalozyme Therapeutics (HALO) Q3 Earnings and Revenues Top Estimates
msn.com - November 2 at 7:20 PM
finance.yahoo.com logoHalozyme Reports Third Quarter 2021 Results
finance.yahoo.com - November 2 at 7:20 PM
finance.yahoo.com logoShould You Buy Halozyme (HALO) Ahead of Earnings?
finance.yahoo.com - November 1 at 12:59 PM
finance.yahoo.com logoWhy the Earnings Surprise Streak Could Continue for Halozyme Therapeutics (HALO)
finance.yahoo.com - October 28 at 3:01 PM
finance.yahoo.com logoHalozyme To Host Third Quarter 2021 Financial Results Webcast and Conference Call
finance.yahoo.com - October 19 at 4:54 PM
nasdaq.com logoFirst Week of June 2022 Options Trading For Halozyme Therapeutics (HALO)
nasdaq.com - October 15 at 6:50 PM
feeds.benzinga.com logoNotable Halozyme Therapeutics Insider Trades $2.7M In Company Stock
feeds.benzinga.com - October 5 at 10:59 AM
benzinga.com logoMichael J Labarre
benzinga.com - October 4 at 6:39 PM
finance.yahoo.com logoNotable Halozyme Therapeutics Insider Trades $1.6M In Company Stock
finance.yahoo.com - October 4 at 6:39 PM
seekingalpha.com logoHalozyme Therapeutics, Inc. 2021 Q2 - Results - Earnings Call Presentation
seekingalpha.com - August 13 at 6:37 PM
benzinga.com logoHalozyme Therapeutics: Q2 Earnings Insights
benzinga.com - August 10 at 12:18 AM
finance.yahoo.com logoHalozyme Therapeutics, inc (HALO) Q2 2021 Earnings Call Transcript
finance.yahoo.com - August 10 at 12:18 AM
msn.com logoBRIEF-Halozyme Reports Second Quarter 2021 Results
msn.com - August 9 at 7:17 PM
nasdaq.com logoHalozyme Therapeutics, Inc. Q2 adjusted earnings Beat Estimates
nasdaq.com - August 9 at 7:17 PM
finance.yahoo.com logoHalozyme Reports Second Quarter 2021 Results
finance.yahoo.com - August 9 at 7:17 PM
finance.yahoo.com logoHalozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates
finance.yahoo.com - August 9 at 7:17 PM
finance.yahoo.com logoWhy Halozyme (HALO) Might Surprise This Earnings Season
finance.yahoo.com - August 5 at 12:48 PM
finance.yahoo.com logoHalozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
finance.yahoo.com - August 2 at 6:08 PM
finance.yahoo.com logoHalozyme to Participate in Canaccord Genuity 41st Annual Growth Conference
finance.yahoo.com - July 30 at 12:43 PM
finance.yahoo.com logoHalozyme To Host Second Quarter 2021 Financial Results Webcast and Conference Call
finance.yahoo.com - July 27 at 5:51 PM
finance.yahoo.com logoThe Big Winner With Johnson & Johnson's Recent FDA Approval
finance.yahoo.com - July 23 at 9:33 AM
nasdaq.com logoThe Halozyme Therapeutics (NASDAQ:HALO) Share Price Has Soared 355%, Delighting Many Shareholders
nasdaq.com - July 19 at 12:25 PM
benzinga.com logoAnalyzing Halozyme Therapeutics's Unusual Options Activity
benzinga.com - July 18 at 8:16 PM
finance.yahoo.com logoJanssen's Darzalex Faspro Wins FDA Approval In Combination With Pomalidomide, Dexamethasone For Multiple Myeloma
finance.yahoo.com - July 12 at 1:24 PM
finance.yahoo.com logoHalozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
finance.yahoo.com - July 12 at 8:24 AM
marketwatch.com logoAntidiabetics Market Share Growth, Size Value, Trends, Rigonal outlook by 2028
marketwatch.com - June 28 at 1:01 PM
finance.yahoo.com logoHalozyme (HALO) Inks Collaboration Deal With Glaxo's HIV Unit
finance.yahoo.com - June 23 at 11:50 AM
benzinga.com logoHalozyme Announces Janssen Receives European...
benzinga.com - June 22 at 5:42 PM
finance.yahoo.com logoHalozyme Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple Myeloma
finance.yahoo.com - June 22 at 5:42 PM
finance.yahoo.com logoHalozyme Collaborates with ViiV Healthcare to Develop Ultra-Long-Acting HIV Meds
finance.yahoo.com - June 22 at 12:42 PM
finance.yahoo.com logoGlaxo (GSK)/Vir Affirm COVID-19 Drug Cuts Hospitalization/Death
finance.yahoo.com - June 22 at 12:42 PM
finance.yahoo.com logoGlaxo Will Face Investors Wednesday. Here’s What to Know.
finance.yahoo.com - June 22 at 12:42 PM
finance.yahoo.com logoDid You Miss Halozyme Therapeutics' (NASDAQ:HALO) Whopping 399% Share Price Gain?
finance.yahoo.com - June 17 at 2:34 PM
finance.yahoo.com logoWhy Is Halozyme Therapeutics (HALO) Down 7.5% Since Last Earnings Report?
finance.yahoo.com - June 9 at 2:28 PM
Get Halozyme Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.